Industry: Pharmaceuticals, Biotechnology
Genitope Corporation is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation’s lead product candidate, MyVax (R) Personalized Immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient’s tumor and is designed to activate the patient’s immune system to identify and attack cancer cells. Genitope Corporation is conducting a pivotal phase 3 clinical trial using MyVax (R) Personalized Immunotherapy in previously untreated follicular non-Hodgkin’s lymphoma patients. Genitope Corporation is based in Redwood City, California. ( www.genitope.com )
Genitope Corporation
6900 Dumbarton Cr
Fremont, California 94555-3651
USA
Tel: (510) 284-3000
Fax: (650) 482-2002